UA119786C2 - Рекомбінантний герпесвірус кої (khv) і вакцина для профілактики захворювання, що викликається khv - Google Patents

Рекомбінантний герпесвірус кої (khv) і вакцина для профілактики захворювання, що викликається khv Download PDF

Info

Publication number
UA119786C2
UA119786C2 UAA201702576A UAA201702576A UA119786C2 UA 119786 C2 UA119786 C2 UA 119786C2 UA A201702576 A UAA201702576 A UA A201702576A UA A201702576 A UAA201702576 A UA A201702576A UA 119786 C2 UA119786 C2 UA 119786C2
Authority
UA
Ukraine
Prior art keywords
knu
infection
recombinant
herpesvirus
vas
Prior art date
Application number
UAA201702576A
Other languages
English (en)
Ukrainian (uk)
Inventor
Ален Франсіс Клод Вандерплассхен
Алэн Франсис Клод Вандэрплассхэн
Original Assignee
Гесваль С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Гесваль С.А. filed Critical Гесваль С.А.
Publication of UA119786C2 publication Critical patent/UA119786C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16061—Methods of inactivation or attenuation
    • C12N2710/16062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Farming Of Fish And Shellfish (AREA)
UAA201702576A 2011-12-30 2012-12-20 Рекомбінантний герпесвірус кої (khv) і вакцина для профілактики захворювання, що викликається khv UA119786C2 (uk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11196171 2011-12-30

Publications (1)

Publication Number Publication Date
UA119786C2 true UA119786C2 (uk) 2019-08-12

Family

ID=47429841

Family Applications (2)

Application Number Title Priority Date Filing Date
UAA201702576A UA119786C2 (uk) 2011-12-30 2012-12-20 Рекомбінантний герпесвірус кої (khv) і вакцина для профілактики захворювання, що викликається khv
UAA201408626A UA114719C2 (uk) 2011-12-30 2012-12-20 Рекомбінантний герпесвірус кої (khv) і вакцина для профілактики захворювання, що викликається khv

Family Applications After (1)

Application Number Title Priority Date Filing Date
UAA201408626A UA114719C2 (uk) 2011-12-30 2012-12-20 Рекомбінантний герпесвірус кої (khv) і вакцина для профілактики захворювання, що викликається khv

Country Status (18)

Country Link
US (2) US20140348875A1 (enExample)
EP (1) EP2797627B1 (enExample)
JP (3) JP5982009B2 (enExample)
CN (1) CN104159609B (enExample)
BR (1) BR112014016117A2 (enExample)
HU (1) HUE053075T2 (enExample)
IL (1) IL232902A0 (enExample)
IN (1) IN2014CN04655A (enExample)
MD (1) MD4481C1 (enExample)
MX (1) MX361408B (enExample)
PH (1) PH12014501388A1 (enExample)
PL (1) PL2797627T3 (enExample)
RS (1) RS61261B1 (enExample)
RU (1) RU2662768C2 (enExample)
SG (1) SG11201403066TA (enExample)
TW (1) TWI484034B (enExample)
UA (2) UA119786C2 (enExample)
WO (1) WO2013098214A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014CN04655A (enExample) * 2011-12-30 2015-09-18 Université de Liège
WO2017177071A1 (en) * 2016-04-08 2017-10-12 William Marsh Rice University Improved galactose utilization
CN112279898B (zh) * 2018-11-05 2022-06-21 共鳞实业(深圳)有限公司 预防或治疗鱼类感染CyHV-2的试剂及其应用
EP3662929A1 (en) * 2018-12-07 2020-06-10 IDT Biologika GmbH A recombinant koi herpesvirus (khv) and a diva vaccine for preventing and/or treating a disease caused by khv
CN110101854B (zh) * 2019-05-14 2022-08-02 四川农业大学 一种鲤疱疹病毒ⅲ型疫苗及其制备方法
CN110452926B (zh) * 2019-08-07 2022-06-17 西北农林科技大学 一种展示CyHV-2膜蛋白的重组杆状病毒及其制备方法和应用
CN110468111B (zh) * 2019-08-07 2022-06-17 西北农林科技大学 一种展示CyHV-2膜蛋白的重组杆状病毒及其制备方法和应用
CN113679832A (zh) * 2021-05-24 2021-11-23 苏州大学 一种利用冷冻干燥制备杆状病毒载鲤疱疹病毒ii型dna疫苗的方法
CN115960903B (zh) * 2022-12-23 2023-09-08 中国水产科学研究院淡水渔业研究中心 一种抑制CyHV-2病毒增殖的反义RNA组、重组载体和纳米粒递送系统及应用
CN120775802B (zh) * 2025-06-13 2026-04-21 中国水产科学研究院珠江水产研究所 一种鲤疱疹病毒3型orf136基因失活株及其制备方法和应用
CN120775801B (zh) * 2025-06-13 2026-07-31 中国水产科学研究院珠江水产研究所 一种鲤疱疹病毒3型orf138基因失活株及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE115862T1 (de) 1989-02-04 1995-01-15 Akzo Nobel Nv Tocole als impfstoffadjuvans.
DE19733364A1 (de) 1997-08-01 1999-02-04 Koszinowski Ulrich H Prof Verfahren zur Klonierung eines großen Virusgenoms
IL153775A0 (en) 2003-01-01 2003-07-31 Yissum Res Dev Co Immunizing fish against viral infection
JP2007223913A (ja) * 2006-02-21 2007-09-06 Kyoritsu Seiyaku Kk コイヘルペスウイルス病ワクチン
EP2011876B1 (en) * 2006-04-13 2014-11-12 National University Corporation Tokyo University of Marine Science and Technology Dna vaccine for koi herpes virus (khv) disease
RU2010111725A (ru) * 2007-08-28 2011-10-10 Юниверсите Де Льеж (Be) Рекомбинантный герпесвирус кои (khv) или герпесвирус 3 семейства карповых (cyhv-3) и вакцина для профилактики заболевания, вызванного khv/cyhv-3 у cyprinus carpio или cyprinus carpio koi
DE102007041332A1 (de) * 2007-08-31 2009-03-05 Siemens Ag Transferchuck zur Übertragung, insbesondere von Wafern
IN2014CN04655A (enExample) * 2011-12-30 2015-09-18 Université de Liège

Also Published As

Publication number Publication date
SG11201403066TA (en) 2014-10-30
BR112014016117A2 (pt) 2018-09-25
EP2797627B1 (en) 2020-10-07
CN104159609B (zh) 2018-05-22
EP2797627A1 (en) 2014-11-05
HUE053075T2 (hu) 2021-06-28
US9931396B2 (en) 2018-04-03
CN104159609A (zh) 2014-11-19
WO2013098214A1 (en) 2013-07-04
MD4481B1 (ro) 2017-05-31
MD20120127A2 (en) 2013-07-31
JP2018078903A (ja) 2018-05-24
TWI484034B (zh) 2015-05-11
MX2014008045A (es) 2014-10-24
MX361408B (es) 2018-12-04
IN2014CN04655A (enExample) 2015-09-18
TW201333201A (zh) 2013-08-16
US20140348875A1 (en) 2014-11-27
US20170028057A1 (en) 2017-02-02
PL2797627T3 (pl) 2021-06-28
JP5982009B2 (ja) 2016-08-31
PH12014501388A1 (en) 2014-09-22
JP2016195593A (ja) 2016-11-24
RS61261B1 (sr) 2021-01-29
UA114719C2 (uk) 2017-07-25
RU2014131474A (ru) 2016-02-20
JP2015503914A (ja) 2015-02-05
RU2662768C2 (ru) 2018-07-31
MD4481C1 (ro) 2017-12-31
IL232902A0 (en) 2014-07-31

Similar Documents

Publication Publication Date Title
JP6845266B2 (ja) 多価組換型鳥ヘルペスウイルス及び鳥類を免疫化するためのワクチン
RU2662768C2 (ru) Рекомбинантный герпесвирус кои (khv) и вакцина для профилактики заболевания, вызываемого khv
ES2288609T3 (es) Virus vaccinia ankara modificado para la vacunacion de neonatos.
HU230576B1 (hu) Kiméra fertőző DNS-klónok, kiméra sertés cirkovírusok, és alkalmazásuk
US11707515B2 (en) Modified Brucella vaccine strain for the treatment of brucellosis
EP3546580B1 (en) Vectors for transforming mycoplasma hyopneumoniae, transformed m.hyopneumoniae strains, and use thereof
CN109310750B (zh) 编码传染性喉气管炎病毒和传染性法氏囊病病毒抗原的重组非致病性马立克氏病病毒构建体
US20220389391A1 (en) F-genotype mumps virus attenuated strain and construction method therefor and application thereof
JP2010536394A (ja) マゴイ(シプリヌス・カルピオ・カルピオ)又はニシキゴイ(シプリヌス・カルピオ・コイ)においてKHV/CyHV−3により引き起こされる疾患の予防のための組み換えコイヘルペスウイルス(KHV)又はコイ科ヘルペスウイルス3(CyHV−3)及びワクチン
TW201812005A (zh) 新穎之魚類病原病毒
US8623381B2 (en) Viral strains derived from the vaccinia virus Lister VACV-107 and uses thereof
Williams et al. A recombinant bovine herpesvirus-4 vectored vaccine delivered via intranasal nebulization elicits viral neutralizing antibody titers in cattle
JP2001186874A (ja) サルモネラワクチン
Glazenburg et al. In vivo recombination of pseudorabies virus strains in mice
EP4720275A2 (en) Vaccine for cats to block toxoplasma oocyst shedding and transmission
Gajdosova et al. Cell-mediated immunity in flavivirus infections. I. Induction of cytotoxic T lymphocytes in mice by an attenuated virus from the tick-borne encephalitis complex and its group-reactive character
KR20250170922A (ko) 아프리카돼지열병 바이러스 배양을 위한 세포주 및 이의 용도
KR20250140913A (ko) 병원성이 약화된 아프리카돼지열병 바이러스 및 이를 포함하는 아프리카돼지열병 예방용 백신 조성물
Preston et al. In vivo and in vitro studies on temperature-sensitive mutants of swine vesicular disease virus
EP4722342A1 (en) Cell line for culturing african swine fever virus and vaccine using same
KR20140033096A (ko) 바이러스성 벡터를 이용한 prrs에 대한 재조합 백신
Marennikova et al. Vaccinia virus